OS Therapies Inc. OSTX 深 滬
等待開盤 09-05 09:30:00 美东时间
2.09
-0.010
-0.48%
華盛通- 最 高2.14
- 今 開2.09
- 成交量 25.97万股
- 最 低 2.02
- 昨 收 2.10
- 總市值 5872.42万
- 52周最高 7.00
- 市盈率 靜 --
- 換手率 0.92%
- 52周最低 1.12
- 委 比 -66.67%
- 總股本 2809.77万
- 歷史最高 7.00
- 量 比 0.38
- 振 幅 5.71%
- 歷史最低 1.12
- 每 手 1
- 風險率 0.91%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多OS Therapies Raises $3.7M for OST-HER2 Launch
The latest announcement is out from OS Therapies Incorporated ( ($OSTX) ). On S...
09-03 04:50
OS Therapies To Provide FDA Meeting Update On OST-HER2 Regulatory Path For Osteosarcoma On September 2, 2025
OS Therapies Inc. (NYSE:OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today announced that it will provide stakeholders with a detailed
08-28 04:13
OS Therapies Reports Progress in Osteosarcoma Treatment
OS Therapies Incorporated ( ($OSTX) ) has released its Q2 earnings. Here is a b...
08-26 12:01
OS Therapies reports Q2 results
OS Therapies press release (NYSE:OSTX): Q2 Reported final EFS data (35% vs. 20%, p = 0.0197) showing a statistically significant benefit from the Company's 40 patient Phase 2b clinical trial for OST-...
08-20 03:21
OS Therapies Q2 EPS $(0.19) Misses $(0.12) Estimate
OS Therapies (AMEX:OSTX) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $(0.12) by 65.22 percent. This is a 26.92 percent increase over losses of $(0.26) per share from the
08-19 18:07
美股大行评级 | DoorDash获上调目标价从230美元升至300美元； 摩根大通上调Shopify目标价从115美元升至179美元
今日重点评级关注：HC Wainwright & Co.：维持FibroGen"买入"评级，目标价从10美元升至43美元；摩根大通：维持Cogent Biosciences"超配"评级，目标价从29美元升至30美元
08-08 09:34
D. Boral Capital Maintains Buy on OS Therapies, Maintains $20 Price Target
D. Boral Capital analyst Jason Kolbert maintains OS Therapies (AMEX:OSTX) with a Buy and maintains $20 price target.
08-08 02:32
OS Therapies Raises $4.2M Through Warrant Exercise
An announcement from OS Therapies Incorporated ( ($OSTX) ) is now available. On...
07-14 20:28
OS Therapies Preps for FDA Meeting as It Eyes Accelerated Approval for Rare Bone Cancer Treatment
OS Therapies (NYSE:OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today provided a clinical and global regulatory update on its
07-10 19:49
OS Therapies OST-HER2 Demonstrates 35% 12-Month Event Free Survival With Favorable Safety Profile Compared To 20% Historical Control
The primary endpoint of 12-month Event Free Survival (EFS) for OST-HER2- treated patients (35%) was statistically significant (p= 0.0194) when compared with peer-reviewed comparable historical control (20%)Company also
06-30 18:36
